In another form of leukemia, chronic myeloid leukemia (CML), PON2 was also identified in an outcome-specific gene expression signature of primary imatinib-resistant patients [150]. This evidence concerns the gene PON2 and chronic myelogenous leukemia, BCR-ABL1 positive.